Medicus Pharma Ltd (TSE:MDCX) has released an update.
Medicus Pharma Ltd. has submitted a comprehensive Phase 2 clinical protocol to the FDA to advance its non-invasive treatment for basal cell carcinoma using its novel micro-needle arrays. The treatment, which has shown promising safety and efficacy in early-stage trials, is poised to offer a new option for patients with this common skin cancer. The submission is a significant step for Medicus, incorporating feedback from previous FDA comments and providing detailed safety data.
For further insights into TSE:MDCX stock, check out TipRanks’ Stock Analysis page.
